Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer

Roca, Enrique Luis and Vinnyk, Yuriy and Bondarenko, Igor and Shparyk, Yaroslav V. and Bariani, Giovanni Mendonca and Abdalla, Kathia and Franke, Fábio and Cruz, Felipe and Romera, Alvaro and Bhamare, Sulabhchandra and Sudalaiandi, Suresh and Ostwal, Vikas S. and Shah, Pradeep and Rahuman, Sajeed and Cubillo, Antonio and Huerga, Camino and Alexandra, Paravisini and Fernandez, Francisco Javier and Millan, Susana (2017) Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer. Journal of Clinical Oncology, 35 (15). e14065-e14065. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)

Text Results of bevacizumab biosimilar TДTА¦-TВ.docx Download (18kB)

Abstract

Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of this study was to demonstrate pharmacokinetics (PK) similarity of BEVZ92 to RMP, in combination in combination with FOLFOX or FOLFIRI, as first-line treatment in patients with mCRC (NCT02069704). Methods: PK analysis for multiple dose studies was conducted, ...

Item Type:	Article
Subjects:	Oncology
Divisions:	Departments > Department of Oncology and Medical Radiology
Depositing User:	Елена Шрамко
Date Deposited:	08 Sep 2017 07:09
Last Modified:	08 Sep 2017 07:09
URI:	http://repo.dma.dp.ua/id/eprint/1926

Actions (login required)

View Item